Ology Bioservices Wins Two Department of Defense Awards Totaling More Than $135 Million ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that the Department of [...]
Ology Bioservices Appoints Vaccines and Biologics Manufacturing Industry Veteran, Brandon Brega, as Chief Operating Officer ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today the appointment [...]
Ology Bioservices to Present at the 30thAnnual Piper Jaffray Healthcare Conference ALACHUA, Fla., November 20, 2018 - - Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that [...]
Ology Bioservices Strengthens Management Team with Addition of Timothy Cooke, Ph.D. as Senior Vice President of Commercial Business ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced [...]
Ology Bioservices Wins $8.4 Million Defense Department Award to Produce Anti-Ebola Medical Countermeasure ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that it was awarded [...]
Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Review of Vaccines. 2017;16(9):883-894. Read More > [...]
Nanotherapeutics, Inc., a company focused on advanced development and manufacturing, today announced that the Company’s proprietary bone void filler product, NanoFUSE® DBM (demineralized bone matrix), has received expanded 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for use in spinal fusion surgery. Specifically, NanoFUSE® DBM has been cleared for use with autograft (transplanted bone from a patient’s own body) as a bone graft extender in the posterolateral spine.
A key challenge in testing and developing new therapies to combat the Ebola virus involves producing sufficient quantities of candidate treatments to conduct clinical trials and then to facilitate commercial scale-up for any product demonstrating effectiveness. Clinical trials are being launched for several promising Ebola therapies and vaccines, and successful results will require massive efforts to produce the millions of doses needed to treat and prevent further spread of the virus.
These are unprecedented times as we respond to avoid the spread of COVID-19, a novel coronavirus that has challenged our routine life. First and foremost, all of us at Ology Bioservices, Inc. hope you and your family members are well, healthy, and safe from harm’s way.
I am reaching out to inform you of steps we are taking to protect our staff, operations and importantly, your ongoing projects at Ology Bio during this time. Our goal is to be prepared to continue serving our clients during this time of uncertainty and confusion. In order to protect our employees and facility, and to keep your projects moving forward, we have implemented the following activities:
Increased our supplies of commonly used laboratory and manufacturing materials, well in advance of the declaration of a pandemic.
Implemented a New Visitor Policy at all locations to further protect the facilities and employees.
Service personnel, vendors, contractors only allowed in our facilities for highly specialized activities.
Persons entering our facilities must sanitize their hands before leaving the entry lobby.
Expanded our IT structure to allow employees with the ability to “work from home” wherever possible.
Providing daycare resources for critical personnel who must conduct their jobs on-site (for example engineering manufacturing, process development and quality).
Cancelled non-essential business travel for all employees of Ology Bioservices.
Cancelled or rescheduled larger meetings or gatherings.
There will be no disruption in communicating with Ology Bio personnel, and our offices will remain open. However, the limited number of personnel physically at our locations will mainly consist of those involved in supporting the process development and manufacturing of our customer’s biological products. Be assured that you will be able to reach all employees through their direct phone lines and email regardless of their location during this crisis.
The entire leadership team at Ology Bioservices remain committed to the health and safety of our employees and our commitments to the customers we serve. This nation has a history of strength and resilience and I am certain that together we will successfully navigate these challenges.